keyword
MENU ▼
Read by QxMD icon Read
search

AITL

keyword
https://www.readbyqxmd.com/read/28337768/tet2-mutations-in-b-cells-of-patients-affected-by-angioimmunoblastic-t-cell-lymphoma
#1
Friederike H Schwartz, Qian Cai, Eva Fellmann, Sylvia Hartmann, Mikko I Mäyränpää, Marja-Liisa Karjalainen-Lindsberg, Christer Sundström, René Scholtysik, Martin-Leo Hansmann, Ralf Küppers
Angioimmunoblastic T cell lymphomas (AITL) frequently carry mutations in the TET2 and IDH2 genes. TET2 mutations represent early genetic lesions as they were already detected in hematopoietic precursor cells of AITL patients. We show by analysis of whole tissue sections and microdissected PD1(+) cells that the frequency of TET2-mutated AITL is presumably even higher than reported (12/13 cases in our collection, 92%). In two thirds of informative AITL (6/9) also a fraction of B cells was TET2-mutated. Investigation of four AITL by TET2 and IGHV gene sequencing of single microdissected B cells showed that between 10-60% of polyclonal B cells in AITL lymph nodes harboured the identical TET2 mutations of the respective T cell lymphoma clone...
March 24, 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28306367/the-clinical-significance-of-epstein-barr-virus-dna-in-peripheral-blood-mononuclear-cells-in-patients-with-non-hodgkin-lymphoma
#2
Yi Chen, Xiaoyun Zheng, Buyuan Chen, Xiaozhu Yang, Jing Zheng, Zhihong Zheng, Ting Yang, Tingbo Liu, Jianda Hu
The aim of the study was to determine the clinical significance of EBV DNA in the peripheral blood mononuclear cells (PBMCs) from the patients with non-Hodgkin lymphoma (NHL). Newly diagnosed patients with NHL were enrolled in the study (n = 328), and clinical data retrospectively analyzed. EBV DNA was detectable in 34.8% of patients, and the positivity rate was 51.6% for T/NK cell subtype and 24.3% for B cell subtype (p < .001). In diffuse large B cell lymphoma (DLBCL), extranodal NK/T-cell lymphoma, nasal type (ENKTL), peripheral T-cell lymphoma not otherwise classified (PTCL...
March 17, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28209473/analysis-of-peripheral-t-cell-lymphoma-diagnostic-workup-in-the-united-states
#3
Eric D Hsi, Steven M Horwitz, Kenneth R Carson, Lauren C Pinter-Brown, Steven T Rosen, Barbara Pro, Massimo Federico, Christian Gisselbrecht, Marc Schwartz, Lisa A Bellm, Mark Acosta, Angela M Collie, Aaron M Gruver, Bartosz J Grzywacz, Samir Turakhia, Andrei R Shustov, Ranjana H Advani, Tatyana Feldman, Mary Jo Lechowicz, Sonali M Smith, Frederick Lansigan, Anil Tulpule, Michael D Craig, John P Greer, Brad S Kahl, Joseph W Leach, Neil Morganstein, Carla Casulo, Steven I Park, Francine M Foss
BACKGROUND: With increased understanding of the unique entities, subtype-specific approaches for peripheral T-cell lymphoma (PTCL) are emerging, and more precise diagnoses are becoming increasingly important. PATIENTS AND METHODS: We analyzed the approach to the histopathologic diagnosis of PTCL using data from the comprehensive oncology measures of peripheral T-cell lymphoma (COMPLETE) study. The COMPLETE trial is a large prospective cohort study of patients with newly diagnosed PTCL in the United States...
January 10, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28194275/inappropriate-costimulation-and-aberrant-dna-methylation-as-therapeutic-targets-in-angioimmunoblastic-t-cell-lymphoma
#4
EDITORIAL
Mathijs Willemsen, Harry C Schouten
Angioimmunoblastic T-cell lymphoma (AITL) is one of the most common subtypes of peripheral T-cell lymphoma. Advances in understanding the mutational landscape of AITL have not resulted in improved prognosis nor consensus regarding optimal first-line and second-line treatment. The recently proposed multistep tumorigenesis model for AITL provides a theoretical framework of AITL oncogenesis. In this model, early mutations in epigenetic modifiers interact with late cooperative mutations to enable malignant transformation...
2017: Biomarker Research
https://www.readbyqxmd.com/read/28188140/angioimmunoblastic-t-cell-lymphoma-with-polyarthritis-resembling-rheumatoid-arthritis
#5
Ralph Yachoui, Nouman Farooq, Jonathan V Amos, Gene R Shaw
Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma (PTCL). AITL typically presents with lymphadenopathy, fever, rash, hepatosplenomegaly, and rarely polyarthritis. We report the case of a 50-year-old female who presented with lymphadenopathy, rash, and symmetric polyarthritis. She was later diagnosed with AITL and was treated with chemotherapy with resolution of arthritis. AITL should be suspected in paitents presenting with rheumatoid-like arthritis and diffuse lymphadenopathy...
December 2016: Clinical Medicine & Research
https://www.readbyqxmd.com/read/28148900/angioimmunoblastic-t-cell-lymphoma-novel-molecular-insights-by-mutation-profiling
#6
Ming Wang, Shaowei Zhang, Shih-Sung Chuang, Margaret Ashton-Key, Eguzkine Ochoa, Niccolo Bolli, George Vassiliou, Zifen Gao, Ming-Qing Du
Angioimmunoblastic T cell lymphoma (AITL) originates from follicular helper T-cells and is characterised by a polymorphic infiltrate with the neoplastic T-cells forming small clusters around the follicle and high endothelial venules. Despite the recent advances in its phenotypic characterisation, the genetics and molecular mechanisms underlying AITL are not fully understood. In the present study, we performed whole exome sequencing in 9 cases of AITL from Taiwan (n = 6) and U.K. (n = 3). We confirmed frequent mutations in TET2 (9/9), DNMT3A (3/9), IDH2 (3/9), RHOA (3/9) and PLCG1 (2/9) as recently reported by others...
March 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/28115369/angioimmunoblastic-t-cell-lymphoma-the-many-faced-lymphoma
#7
REVIEW
Matthew A Lunning, Julie M Vose
Angioimmunoblastic T-cell lymphoma (AITL) is an uncommon subtype of mature peripheral T-cell lymphoma (PTCL). The history of AITL is much longer and deeper than the literature would suggest given the many names that have preceded it. Advanced-stage disease is common with uncharacteristic laboratory and autoimmune findings that often slow or mask the diagnosis. Significant strides in the immunohistochemical and molecular signature of AITL have brought increased ability to diagnose this uncommon type of PTCL...
March 2, 2017: Blood
https://www.readbyqxmd.com/read/28053548/recombinant-human-endostatin-in-combination-with-chop-regimen-for-peripheral-t-cell-lymphoma
#8
Qunling Zhang, Junning Cao, Kai Xue, Xiaojian Liu, Dongmei Ji, Ye Guo, Xiaonan Hong
Peripheral T cell lymphoma (PTCL) has a poor prognosis. Overexpression of vascular endothelial growth factor (VEGF) might contribute to the poor prognosis of PTCL and could be the target of novel therapy. The efficacy and safety of recombinant human endostatin (Endostar) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (ECHOP) have been explored in 15 PTCL patients. The objective response rate was 80%, with 53.3% patients having achieved complete response (CR) rate. The CR rate was 100% (3/3) in angioimmunoblastic T cell lymphoma (AITL) patients compared to only 36...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28050005/angioimmunoblastic-t-cell-lymphoma-associated-with-iga-nephropathy
#9
Yukinori Harada, Kei Sakai, Shiho Asaka, Kazutaka Nakayama
Few cases of IgA nephropathy with angioimmunoblastic T-cell lymphoma (AITL) have been reported. We herein present the case of a 79-year-old Japanese man with AITL and IgA nephropathy. The patient presented with generalized edema, fatigue, and fever. Laboratory investigations revealed polyclonal gammopathy with a high level of IgA, microscopic hematuria, proteinuria, and some other immunological abnormalities. Computed tomography revealed generalized lymphadenopathy. A diagnosis of AITL and IgA nephropathy was made based on inguinal lymph node and renal biopsies...
2017: Internal Medicine
https://www.readbyqxmd.com/read/27995879/-comparison-of-allogeneic-or-autologous-hematopoietic-stem-cell-transplant-for-high-risk-peripheral-t-cell-lymphomas
#10
Q L Wang, H W Huang, Z M Jin, X W Tang, H Y Qiu, C C Fu, Y Han, M Miao, H R Chang, A N Sun, D P Wu
Objective: To evaluate the efficacy of auto-HSCT and allo-HSCT in the treatment of high risk peripheral T cell lymphoma (PTCL). Methods: From July 2007 to July 2014, 60 cases of high risk PTCL were analyzed retrospectively. Results: All 60 patients were at high risk group (carried with IPI≥3), with a median age of 31 (12-58) years old. Of the 60 cases, 22 were PTCL-not otherwise specified (PTCL-NOS), 22 ALK negative anaplastic large cell lymphoma (ALK-negative ALCL) and 16 angioimmunoblastic T-cell lymphoma (AITL)...
November 14, 2016: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/27983760/the-survival-outcome-of-patients-with-relapsed-refractory-peripheral-t-cell-lymphoma-not-otherwise-specified-and-angioimmunoblastic-t-cell-lymphoma
#11
Dai Chihara, Michelle A Fanale, Roberto N Miranda, Mansoor Noorani, Jason R Westin, Loretta J Nastoupil, Fredrick B Hagemeister, Luis E Fayad, Jorge E Romaguera, Felipe Samaniego, Francesco Turturro, Hun J Lee, Sattva S Neelapu, M Alma Rodriguez, Michael Wang, Nathan H Fowler, Richard E Davis, L Jeffrey Medeiros, Chitra Hosing, Yago L Nieto, Yasuhiro Oki
Survival outcome of patients with peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL) who experience disease progression/relapse remains very poor. A total of 321 patients, newly diagnosed with PTCL-NOS (n = 180) or AITL (n = 141) between 1999 and 2015, were analysed. Failure-free survival (FFS) and overall survival (OS) were calculated from the time of first disease progression (FFS1, OS1), from second disease progression (FFS2, OS2) and from third progression (FFS3, OS3)...
March 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/27982416/how-i-manage-peripheral-t-cell-lymphoma-not-otherwise-specified-and-angioimmunoblastic-t-cell-lymphoma-current-practice-and-a-glimpse-into-the-future
#12
REVIEW
Norbert Schmitz, Laurence de Leval
Peripheral T-cell lymphoma (PTCL), not otherwise specified (NOS) and angioimmunoblastic T-cell lymphoma (AITL) are the most frequent of more than 20 mature PTCL entities featuring a broad spectrum of morphological, immunophenotypic, molecular and clinical characteristics. Unfortunately, recent progress in understanding the (epi)genetic background of PTCL has not been met with similar advances in treatment. Thus, CHO(E)P [cyclophosphamide, doxorubicin, vincristine, and prednisone (plus etoposide)] remains standard first-line therapy...
March 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/27956631/the-idh2-r172k-mutation-associated-with-angioimmunoblastic-t-cell-lymphoma-produces-2hg-in-t-cells-and-impacts-lymphoid-development
#13
François Lemonnier, Rob A Cairns, Satoshi Inoue, Wanda Y Li, Aurélie Dupuy, Sophie Broutin, Nadine Martin, Virginie Fataccioli, Romain Pelletier, Andrew Wakeham, Bryan E Snow, Laurence de Leval, Anais Pujals, Corinne Haioun, Angelo Paci, Erica R Tobin, Rohini Narayanaswamy, Katherine Yen, Shengfang Jin, Philippe Gaulard, Tak W Mak
Oncogenic isocitrate dehydrogenase (IDH)1 and IDH2 mutations at three hotspot arginine residues cause an enzymatic gain of function that leads to the production and accumulation of the metabolite 2-hydroxyglutarate (2HG), which contributes to the development of a number of malignancies. In the hematopoietic system, mutations in IDH1 at arginine (R) 132 and in IDH2 at R140 and R172 are commonly observed in acute myeloid leukemia, and elevated 2HG is observed in cells and serum. However, in angioimmunoblastic T-cell lymphoma (AITL), mutations are almost exclusively restricted to IDH2 R172, and levels of 2HG have not been comprehensively measured...
December 27, 2016: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/27921272/bcl6-locus-is-hypermethylated-in-angioimmunoblastic-t-cell-lymphoma
#14
Shoko Nishizawa, Mamiko Sakata-Yanagimoto, Keiichiro Hattori, Hideharu Muto, Tran Nguyen, Koji Izutsu, Kenichi Yoshida, Seishi Ogawa, Naoya Nakamura, Shigeru Chiba
BCL6, a master transcription factor for differentiation of follicular helper T (TFH) cells, is highly expressed in angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphomas (PTCL) containing tumor cells with TFH features. TET2, encoding an epigenetic regulator, is frequently mutated in AITL/PTCL. We previously reported that Tet2 knockdown mice developed T-cell lymphomas with TFH features. Hypermethylation of the Bcl6 locus followed by BCL6 upregulation was thought to be the key event for lymphoma development in mice...
April 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/27885817/serum-ferritin-level-is-a-prognostic-marker-in-patients-with-peripheral-t-cell-lymphoma
#15
S Koyama, S Fujisawa, R Watanabe, M Itabashi, D Ishibashi, Y Ishii, Y Hattori, Y Nakajima, K Motohashi, H Takasaki, R Kawasaki, C Hashimoto, E Yamazaki, H Koharazawa, S Takemura, N Tomita, R Sakai, S Motomura, H Nakajima
INTRODUCTION: The prognostic value of serum ferritin level in patients with peripheral T-cell lymphoma (PTCL) remains unknown. METHODS: We retrospectively analyzed clinical data from 78 consecutive patients with newly diagnosed PTCL that were treated with anthracycline-containing regimens between 1998 and 2011. RESULTS: The patients consisted of 50 males and 28 females with a median age of 64 years (range, 16-83 years). The subtypes of PTCL were 39 PTCL, not otherwise specified and 39 angioimmunoblastic T-cell lymphoma (AITL)...
February 2017: International Journal of Laboratory Hematology
https://www.readbyqxmd.com/read/27863842/development-of-t-follicular-helper-cells-and-their-role-in-disease-and-immune-system
#16
REVIEW
Sadegh Eivazi, Salman Bagheri, Mohammad Sadegh Hashemzadeh, Majdedin Ghalavand, Elmira Safaie Qamsari, Ruhollah Dorostkar, Maryam Yasemi
The T follicular helper cells (TFH) are a subset of CD4+ T cells specialized to regulate antibody responses. The production of these cells is associated with the dendritic cells (DCs) and B cells. TFH cells help B cells form germinal centers (GC) differentiate into memory and plasma cells (antibody-secreting cells) as humoral responses. In addition, there is strong evidence that TFH cells play a pivotal role in the development of long-lived humoral immunity. Molecular factors such as transcription factors, surface receptors, cytokine and micro RNAs are involved in the formation of TFH cells...
December 2016: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/27832711/discussion-of-18f-fdg-pet-ct-imaging-characteristics-and-diagnostic-values-of-angioimmunoblastic-t-cell-lymphoma
#17
Dan Shao, Qiang Gao, Chang-Hong Liang, Shu-Xia Wang
The aim of this study was to discuss (18)F-FDG PET/CT imaging characteristics and diagnostic values of angioimmunoblastic T-cell lymphoma (AITL). The PET/CT features of 24 cases of pathologically confirmed AITL were analyzed. The individual and total diagnostic values of 13 sites using computed tomography (CT) and positron emission tomography (PET)/CT were calculated. The maximum standard uptake value (SUVmax) of lesions with lymph node infiltration and extranodal organ infiltration were 5.4-25.1 (median, 9...
November 10, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27718766/value-of-interim-fdg-pet-ct-for-predicting-outcome-of-patients-with-angioimmunoblastic-t-cell-lymphoma
#18
Seung Hwan Moon, Ah Young Lee, Won-Seog Kim, Seok Jin Kim, Young Seok Cho, Yearn Seong Choe, Byung-Tae Kim, Kyung-Han Lee
Subjects were 45 patients with angioimmunoblastic T-cell lymphoma (AITL) who underwent 2-[(18)F]-fluoro-2-deoxy-d-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) at baseline and interim after 2-4 cycles. Predictors of progression-free survival (PFS) and overall survival (OS) were assessed. Positive interim PET/CT (Deauville score ≥3) was a significant independent predictor of poor PFS (Hazard ratio, 4.42; p=.028), and showed marginal significance to predict OS (p=.065). Less than 60% decrease in the average change of maximum standardized uptake value normalized by lean body mass (SULmax) also was a significant independent predictor of poor PFS (Hazard ratio, 12...
October 9, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27711130/highly-diverse-efficacy-of-salvage-treatment-regimens-for-relapsed-or-refractory-peripheral-t-cell-lymphoma-a-systematic-review
#19
Ya-Ting Yang, Cheng-Jeng Tai, Chiehfeng Chen, Hong-Cheng Wu, Natalia Mikhaylichenko, Hsien-Tsai Chiu, Yun-Yi Chen, Yi-Hsin Elsa Hsu
BACKGROUND: The goal of this study was to perform a systematic review to examine the efficacy and safety of various salvage therapy regimens on patients with relapsed/refractory PTCL. METHOD: The electronic searches were performed using PubMed, Cochrane Library, EMBASE, and Web of Science from inception through June 2015, with search terms related to relapsed/refractory PTCL, salvage chemotherapy regimens, and clinical trials. An eligible study met the following inclusion criteria: (1) Patients had refractory or relapsed PTCL; (2) drug regimens were used for salvage therapy; (3) the study was a clinical trial; (4) the study reported on a series of at least 10 patients of PTCL...
2016: PloS One
https://www.readbyqxmd.com/read/27648317/long-term-treatment-with-romidepsin-in-patients-with-peripheral-t-cell-lymphoma
#20
Claudius Irlé, Jonathan Weintraub
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas. Angioimmunoblastic T-cell lymphoma (AITL) is a common subtype of PTCL, and patients with AITL typically have a poor prognosis with limited treatment options. Clinical studies have demonstrated the activity of romidepsin, a structurally unique, potent, bicyclic class 1 selective histone deacetylase inhibitor, in patients with relapsed or refractory AITL. In the case presented herein, we describe a patient treated with single-agent romidepsin at first diagnosis of AITL, resulting in complete remission for over 2 years and leading to the use of maintenance dosing...
2016: Case Reports in Hematology
keyword
keyword
70155
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"